Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
Samuel Yamshon(Cornell University), Jia Ruan(Cornell University), Richard R. Furman(Cornell University), Paul J. Christos(Cornell University), Bijal Shah(Boston College), Gui Zhen Chen(University of Washington), Jakub Svoboda(UPMC Hillman Cancer Center), Caitlin Gribbin(Cornell University), Peter Martin(Northwestern University), Stephen J. Schuster(Hospital of the University of Pennsylvania), John P. Leonard(New York University), Sonali M. Smith(University of Chicago)
Cited by 10
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k